My Ultimate Sign-in System Made Me Invincible Chapter 494 Moral Vs Logic (2)

Official Announcement 📢Nova Technologies issues the following update regarding regulatory oversight for the Nova Medical Nanites clinical trial.

Observer ParticipationNova Technologies confirms that regulatory bodies globally have officially verified observer involvement in the clinical trial. The following institutions have provided confirmation:• World Health Organization• Food and Drug Administration• Centers for Disease Control and Prevention• European Medicines Agency• National Medical Products Administration• Medicines and Healthcare products Regulatory Agency

National Government ObserversObserver delegations from 79 nations across all inhabited continents have been confirmed. A complete list of participating countries will be released separately once all delegations are finalized.

Access Rights for ObserversParticipating observers will be granted:• Real-time access to trial data and patient results throughout their stay at the facility• Direct observation of trial procedures, contingent upon volunteer consent and privacy regulations• Access to Nova Technologies medical personnel for data clarification and inquiries• Complete incident logs and monitoring data during the observation window• Permission for photography and recording in designated common areas and observation zonesPhotography and recording remain restricted in active treatment zones unless explicit volunteer consent is granted.

Restrictions on Observer AccessNova Technologies maintains transparency regarding the limits of observer access. Observers will NOT have access to:• Nova Technologies' proprietary technology architecture• Operational infrastructure at the system level• Intellectual property of any kind• Patient data beyond what the individual volunteer has authorized for release• Information exceeding the scope of trial observation and data validation

Observer ConductObservers are present strictly in a validation capacity. While they may document, question, and verify, they are strictly prohibited from interfering with trial operations, instructing company staff, or attempting to access areas beyond their authorized scope. Any observer violating these rules will be immediately removed from the facility.

Observer Identification RequirementsConfirmed institutions must submit comprehensive identification for their observers within 21 days. Required details include:• Full legal name• Professional credentials and qualifications• Current institutional affiliation and position• Government-issued identification• Security clearance documentation, where applicableObserver selections are subject to final security screening by Nova Technologies. Failure to submit identification within the deadline may result in the forfeiture of observer allocation.

Observer Data AccessSubject to explicit volunteer consent, observers may be provided with:• De-identified case studies (requiring subject permission)• Aggregate treatment outcome data• Statistical analysis across condition categories• Technical documentation regarding monitoring protocolsNote that all individual medical information requires explicit volunteer authorization prior to sharing.

Transport and AccommodationObservers will be flown to Nova Technologies' Lunar Base Sanctuary via private shuttle from their designated departure airports. Coordination details will be sent directly to each institution via a company liaison. Each observer will receive private lodging, full meals, and unrestricted communication access to their home base. Return transport will be provided at the end of the observation period. Note: Observation duration is at the sole discretion of Nova Technologies, though extended stays may be granted on a case-by-case basis. Institutions wishing to participate that have not yet confirmed must do so within 7 days, as later requests cannot be accommodated.

— Nova Technologies

______

Official Announcement 📢Nova Technologies announces an adjustment to the Medical Nanite clinical trial schedule. The start date has been moved forward; the trial will now commence in 57 days—a 30-day acceleration from previously stated projections due to increased efficiency in preparation and facility readiness.

Impact on VolunteersVolunteer selection will follow this accelerated timeline. Participants will be notified 45 days before the start date to allow time for travel and documentation. Selected volunteers will receive detailed preparation materials, direct medical coordination support, comprehensive briefings, and transportation assistance. Those requiring more than the allotted 45 days should specify this during the confirmation phase.

Impact on ObserversObserver institutions will be notified of their status within 14 days. Confirmed observers will receive facility briefing materials, transport schedules, and protocol documentation. Arrivals will be synchronized with trial phases for maximum utility.

Volunteer SelectionThe selection announcement will be released within 12 days, detailing criteria, application processes, required documents, eligibility, and priority condition categories.

Timeline Summary• Today: Timeline adjustment announced (57 days until commencement)• Within 12 days: Volunteer selection process officially announced• 42 days from today: Selected volunteers notified (15 days pre-trial)• 57 days from today: Clinical trial commences

— Nova Technologies

***

The updates were pushed to all LucidNet followers, instantly pausing the ongoing ideological wars as users flocked to read the data. The company largely ignored the pressing arguments regarding affordability and accusations of artificial scarcity, sticking to their standard, detached tone. Predictably, the reaction was immediate and polarized.

One outspoken critic posted: "Nova Technologies has completely ignored our concerns regarding accessibility. They are inviting 79 nations to watch a show where healthcare is treated like entertainment, utilizing subscription tiers and lottery systems to decide who receives life-saving treatment. They are choosing who lives and dies based on monthly fees." The post generated 43,000 likes in under twenty minutes, mirroring the frustration of many who felt silenced.

Another user remarked: "They are being incredibly clear about what observers can and cannot see. Real-time data? Sure. But look at what is off-limits: proprietary architecture, system infrastructure, and intellectual property. They are using this 'transparency' as a shield to lock away the actually valuable secrets."

Conversely, supporters were quick to defend the stance. "Let's be real," one user argued, "they are allowing 79 nations to send delegations. That is unprecedented. Name one pharmaceutical giant that does that. I'm waiting. They are providing real-time data access as it happens, not months-old curated reports. Unlike the traditional healthcare system, they actually respect patient privacy."

Another supporter added, "People crying about 'affordability' are missing the point. The Essential tier is cheaper than a phone bill and offers treatments that cost hundreds of thousands elsewhere."

Regarding the accelerated timeline, one supporter wrote: "They moved the trial forward by THIRTY DAYS. The pharma industry usually delays trials to squeeze patent profits. Nova is rushing to save lives, and people are still calling them villains? Make it make sense."

A user with regulatory experience chimed in: "I work in pharma regulation, and what Nova is doing is unheard of. We usually scramble for months to get the level of data access they are just handing out. The secrecy surrounding proprietary tech is standard practice; you don't leak trade secrets just because you're running a trial. People need to use their heads."

Despite the technical justifications, moral critics remained firm. One noted: "I don't care about industry standards; the industry is broken. Comparing Nova to companies charging 3,000% markups on insulin isn't a defense. Life-saving tech should be a public good, not a profit center. They have created a system that mimics transparency while maintaining total, unaccountable control at their sole discretion."

Realists countered: "It's their facility, their tech, and their trial. They are allowing observation as a courtesy, not as a legal obligation. They are operating at the Lunar Base Sanctuary—a location outside of any singular nation's jurisdiction. They could literally conduct this experiment in total secrecy if they wanted to. The fact that they aren't is a massive gesture of goodwill."

The debate culminated in a viral realization: "We are arguing over a company that announced this technology FOUR DAYS AGO and is starting trials in FIFTY-SEVEN DAYS. In the pharma world, that is light years ahead of the usual decade-long process. Speed alone is saving thousands of lives, regardless of the commercial model."

Nova Technologies maintained its characteristic silence, offering no further rebuttal. The structure was locked, the timeline was fixed, and the background noise of the internet had no impact on the boardrooms. Logistics were already in motion, as delegations prepared for the most observed medical trial in human history.